Table 4.
Rosiglitazone meta-analyses for myocardial infarction
| Method (fixed or random effects), and data sources | Single zero event trials | Zero total event trials | Continuity correction | Effect estimate (95% CI) | No of trials |
|---|---|---|---|---|---|
| Peto (fixed) | |||||
| IPD only | Included | Excluded | None | OR 1.30 (1.02 to 1.67)* | 30 |
| IPD+RECORD | Included | Excluded | OR 1.17 (0.99 to 1.38) | 31 | |
| IPD+summary | Included | Excluded | OR 1.19 (0.96 to 1.48) | 60 | |
| IPD+summary+RECORD | Included | Excluded | OR 1.13 (0.97 to 1.32) | 61 | |
| Mantel-Haenszel (fixed) | |||||
| IPD only | Included | Excluded | Constant continuity correction of 0.5 | OR 1.25 (0.99 to 1.60) | 30 |
| RR 1.25 (0.99 to 1.58) | 30 | ||||
| IPD+RECORD | Included | Excluded | OR 1.15 (0.98 to 1.36) | 31 | |
| RR 1.14 (0.98 to 1.33) | 31 | ||||
| IPD+summary | Included | Excluded | OR 1.13 (0.92 to 1.39) | 60 | |
| RR 1.13 (0.92 to 1.38) | 60 | ||||
| IPD+summary+RECORD | Included | Excluded | OR 1.10 (0.95 to 1.28) | 61 | |
| RR 1.10 (0.95 to 1.27) | 61 | ||||
| IPD only | Included | Included | OR 1.25 (0.98 to 1.59) | 33 | |
| RR 1.24 (0.98 to 1.57) | 33 | ||||
| IPD+RECORD | Included | Included | OR 1.15 (0.97 to 1.35) | 34 | |
| RR 1.14 (0.98 to 1.33) | 34 | ||||
| IPD+summary | Included | Included | OR 1.11 (0.92 to 1.34) | 136 | |
| RR 1.11 (0.93 to 1.33) | 136 | ||||
| IPD+summary+RECORD | Included | Included | OR 1.09 (0.95 to 1.26) | 137 | |
| RR 1.09 (0.95 to 1.25) | 137 | ||||
| Dersimonian and Laird (random) | |||||
| IPD only | Included | Excluded | Constant continuity correction of 0.5 | OR 1.17 (0.92 to 1.51) | 30 |
| RR 1.16 (0.91 to 1.49) | 30 | ||||
| IPD+RECORD | Included | Excluded | OR 1.11 (0.94 to 1.32) | 31 | |
| RR 1.10 (0.94 to 1.29) | 31 | ||||
| IPD+summary | Included | Excluded | OR 1.09 (0.88 to 1.35) | 60 | |
| RR 1.09 (0.88 to 1.34) | 60 | ||||
| IPD+summary+RECORD | Included | Excluded | OR 1.08 (0.92 to 1.26) | 61 | |
| RR 1.07 (0.92 to 1.24) | 61 | ||||
| IPD only | Included | Included | OR 1.17 (0.91 to 1.51) | 33 | |
| RR 1.16 (0.91 to 1.48) | 33 | ||||
| IPD+RECORD | Included | Included | OR 1.11 (0.94 to 1.31) | 34 | |
| RR 1.10 (0.94 to 1.29) | 34 | ||||
| IPD+summary | Included | Included | OR 1.08 (0.89 to 1.31) | 136 | |
| RR 1.07 (0.89 to 1.30) | 136 | ||||
| IPD+summary+RECORD | Included | Included | OR 1.07 (0.93 to 1.24) | 137 | |
| RR 1.07 (0.92 to 1.23) | 137 | ||||
| Mantel-Haenszel (fixed) | |||||
| IPD only | Included | Excluded | Treatment arm correction | OR 1.29 (1.01 to 1.64) | 30 |
| RR 1.28 (1.01 to 1.63) | 30 | ||||
| IPD+RECORD | Included | Excluded | OR 1.16 (0.99 to 1.37) | 31 | |
| RR 1.15 (0.99 to 1.35) | 31 | ||||
| IPD+summary | Included | Excluded | OR 1.17 (0.96 to 1.44) | 60 | |
| RR 1.17 (0.96 to 1.43) | 60 | ||||
| IPD+summary+RECORD | Included | Excluded | OR 1.12 (0.97 to 1.31) | 61 | |
| RR 1.12 (0.97 to 1.29) | 61 | ||||
| IPD only | Included | Included | OR 1.29 (1.01 to 1.64) | 33 | |
| RR 1.28 (1.01 to 1.62) | 33 | ||||
| IPD+RECORD | Included | Included | OR 1.16 (0.99 to 1.37) | 34 | |
| RR 1.15 (0.99 to 1.35) | 34 | ||||
| IPD+summary | Included | Included | OR 1.14 (0.95 to 1.38) | 136 | |
| RR 1.14 (0.95 to 1.37) | 136 | ||||
| IPD+summary+RECORD | Included | Included | OR 1.11 (0.96 to 1.28) | 137 | |
| RR 1.11 (0.96 to 1.27) | 137 | ||||
| Dersimonian and Laird (random) | |||||
| IPD only | Included | Excluded | Treatment arm correction | OR 1.18 (0.92 to 1.53) | 30 |
| RR 1.17 (0.92 to 1.50) | 30 | ||||
| IPD+RECORD | Included | Excluded | OR 1.12 (0.94 to 1.32) | 31 | |
| RR 1.11 (0.94 to 1.30) | 31 | ||||
| IPD+summary | Included | Excluded | OR 1.10 (0.89 to 1.37) | 60 | |
| RR 1.10 (0.89 to 1.36) | 60 | ||||
| IPD+summary+RECORD | Included | Excluded | OR 1.09 (0.92 to 1.27) | 61 | |
| RR 1.08 (0.93 to 1.25) | 61 | ||||
| IPD only | Included | Included | OR 1.18 (0.92 to 1.52) | 33 | |
| RR 1.17 (0.91 to 1.50) | 33 | ||||
| IPD+RECORD | Included | Included | OR 1.12 (0.94 to 1.32) | 34 | |
| RR 1.11 (0.94 to 1.30) | 34 | ||||
| IPD+summary | Included | Included | OR 1.08 (0.89 to 1.32) | 136 | |
| RR 1.08 (0.89 to 1.31) | 136 | ||||
| IPD+summary+RECORD | Included | Included | OR 1.08 (0.93 to 1.25) | 137 | |
| RR 1.07 (0.93 to 1.23) | 137 | ||||
IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.
For all analyses, numbers of myocardial infarction events observed among total population of patients was as follows: IPD only, rosiglitazone population: 147 events among 11 837 patients; IPD only, control population: 133 events among 9319 patients; RECORD, rosiglitazone population: 167 events among 2226 patients; RECORD, control population: 158 events among 2232 patients; summary, rosiglitazone population: 43 events among 12 630 patients; summary, control population: 40 events among 11 053 patients.
*
P=0.04; this was the only significant P value.